Fully Integrated Platform

Ascletis is an innovative R&D driven biotech with two commercial products and listed on Hong Kong Stock Exchange (Ascletis, 1672.HK). Ascletis’ mission is to address unmet medical needs in three therapeutic areas: viral, cancer and fatty liver diseases. Led by a management team with deep expertise and a proven track record, Ascletis has developed a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization.

Antibody-based Immunotherapy

ASC22,PD-L1 antibody for HBV, first-in-class, subcutaneous, room temperature stable,phase 2 ready.

First/Best-in-Class Small Molecules

ASC40, first-in-class FASN inhibitor for NASH, phase 2. ASC09, best-in-class HIV protease inhibitor with unprecedented genetic barrier, phase 2.


ASC06, first systematically delivered, dual-targeting siRNA for liver cancer, phase 1.

Imagine what you could do at Ascletis

Our greatest assets are our employees. Ascletis is an equal opportunity employer and focused on providing a positive work environment where courageous innovation is encouraged and expected.

Our mission is to become a world-class biotechnology company addressing unmet medical needs in three therapeutic areas: anti-viral, cancer and fatty liver disease, for the patients in China and worldwide. Our highly talented team of researchers and professionals who passionately share in this common mission.

We offer competitive salaries and benefits that reward employees for their contribution to the company. If you’re interested in learning more about what we have to offer, please email your CV to hr@ascletis.com. We will look to match any current and upcoming openings to your area of expertise.

多盈娱乐官网唯一注册_博猫平台网址注册开户_365外围赌场 xpj娱乐官方客户端 以太坊最新价格 以太坊价格预测 瑞波币今日行情走势 以太坊注册官网 hg1717皇冠下载 众博平台登录 必发365娱乐官方网站 现金彩票开户官网 必发彩票导航网站 彩票注册平台娱乐 mg4355游戏平台官方网站 金沙3983网址平台 现金网赌盘口